Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma

Table 1 Characteristics of the patients with and without hepatocellular carcinoma

	HCC (+)	HCC (-)	P vaule
n	32	29
Age	71.0 ± 11.2	61.8 ± 11.3	0.0064
Sex (M/F)	19/13	17/12	0.9523
Decreased BW (kg)	1.68 ± 3.81	3.43 ± 3.00	0.0130
Decreased BW (%)	2.56 ± 5.23	5.36 ± 4.27	0.0127
TLV (3.75/7.5/15 mg/d)	3/24/5	2/22/5	0.9325
Furosemide (≤ 20/20 <, ≤ 40/> 40 mg/d)	8/13/11	8/11/10	0.9671
Spironolactone (≤ 25/25 <, ≤ 50/> 50 mg/d)	2/8/22	2/10/17	0.6986
Portal thrombus (+/-)	8/24	0/29	0.0039
Albumin (g/dL)	2.64 ± 0.38	2.31 ± 0.48	0.0045
CPT score	10.7 ± 2.0	11.1 ± 1.7	0.2357
BUN (mg/dL)	21.3 ± 8.2	18.6 ± 10.2	0.1584
Na (mEq/L)	134.1 ± 5.7	134.6 ± 5.4	0.5620
K (mEq/L)	4.02 ± 0.67	3.85 ± 0.55	0.4827
eGFR (mL/min)	58.66 ± 21.78	69.52 ± 40.39	0.8285
LDH (IU/L)	293.8 ± 164.1	259.6 ± 107.2	0.4228
Platelet count (× 104/μL)	10.87 ± 5.38	12.40 ± 11.35	0.8852
T factor of TNM classification (T1/T2/T3a and T3b)	6/13/13	-	-

CPT score: Child-Pugh-Turcotte score; BW: Body weoght; HCC: Hepatocellular carcinoma; eGFR: Estimated glemerular filtration rate; BUN: Blood urea nitrogen; LDH: Lactate dehydrogenase; TLV: Tolvaptan.